南京聚隆(300644.SZ):以1650萬元增資並控股東莞旺順 以其為平台佈局高温尼龍改性、特種工程塑料改性、降解塑料改性及製品業務板塊
格隆匯3月22日丨南京聚隆(300644.SZ)公佈,公司第五屆董事會第六次會議決議,審議通過《關於公司對外投資暨增資並控股東莞旺順生物科技有限公司的議案》。
依據公司聘請的審計機構天衡會計師事務所(特殊普通合夥)出具的《東莞旺順生物科技有限公司2021年度財務報表審計報吿》【天衡審字(2022)00260)號】,董事會經審議同意公司以現金1650萬元增資並控股東莞旺順生物科技有限公司(“東莞旺順”),並以其為平台佈局高温尼龍改性、特種工程塑料改性、降解塑料改性及製品業務板塊。此次增資後,東莞旺順註冊資本變更為3000萬元,其中公司持股比例為55%。通過此次對外投資可優化公司產品結構,進一步加強公司在珠三角區域的發展優勢,提升區域市場競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.